Clinical trials have found that sodium-glucose cotransporter-2 (SGLT2) inhibitors reduce serum urate levels by 0.6-1.5 mg/dL, which might contribute to cardiovascular protection. Urate is the final degradation product of purine nucleotides in humans who lack u... ...

请注册登录后继续浏览